Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: SWOG S0904

BACKGROUND: Vandetanib is an oral tyrosine kinase inhibitor of VEGFR-2/3, EGFR and RET, which has demonstrated clinical activity as a single agent and in combination with taxanes. We explored the efficacy, safety and toxicity of docetaxel and vandetanib in women with recurrent ovarian cancer (OC). M...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Coleman, Robert L., Moon, James, Sood, Anil K., Hu, Wei, Delmore, James E., Bonebrake, Albert J., Anderson, Garnet L, Chambers, Setsuko K., Markman, Maurie
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4098779/
https://ncbi.nlm.nih.gov/pubmed/24709487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2014.03.005
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker